{"filing":{"accession_number":"0001654954-26-009023","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"a4743z.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426009023/a4743z.htm"},"events":[{"id":35941,"run_id":33129,"accession_number":"0001654954-26-009023","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"GSK announced positive phase Ib clinical trial data for risvutatug rezetecan (Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate in extensive-stage small cell lung cancer, showing a 61% overall response rate at the 8 mg/kg dose. This is a material clinical development milestone supporting accelerated development and dose selection for an ongoing global phase III trial, representing significant progress in a key oncology program with multiple regulatory designations (Breakthrough Therapy, orphan drug, PRIME designation).","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":40176,"accession_number":"0001654954-26-009023","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"GSK announced positive phase Ib clinical trial data for risvutatug rezetecan (Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate in extensive-stage small cell lung cancer, showing a 61% overall response rate at the 8 mg/kg dose. This is a material clinical development milestone supporting accelerated development and dose selection for an ongoing global phase III trial, representing significant progress in a key oncology program with multiple regulatory designations (Breakthrough Therapy, orphan drug, PRIME designation).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:26:37.941036+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-10-19"}]}